These findings demonstrate that dual blockade of IL6 and CCR2 pathways effectively enhances the antitumor activity of NK cells in HPV-negative HNSCC, providing a novel strategy for treating this type of cancer. This evidence concerns the gene CCR2 and head and neck squamous cell carcinoma.